Bessemer Group’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Bessemer Group's NRIX Position: Q3 2026 in Review
Bessemer Group reduced its Nurix Therapeutics (NRIX) stake by 0.41% in Q3 2026, selling an estimated $30.9K and leaving 304,762 shares worth $7.23M. The position accounts for 0.01% of the portfolio, ranked #467.
Bessemer Group first reported a position in NRIX in Q1 2021 and has held it in 23 quarters since. The position peaked at $9.8M in Q3 2021. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Bessemer Group held 304,762 shares of Nurix Therapeutics worth $7.23M as of Q3 2026.
- Bessemer Group sold 1,241 Nurix Therapeutics shares in Q3 2026, an estimated $30.9K.
- Nurix Therapeutics made up 0.01% of Bessemer Group's portfolio in Q3 2026, its #467 holding.
- Bessemer Group first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 23 quarters since.
- Bessemer Group's Nurix Therapeutics position peaked at $9.8M in Q3 2021.
- 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.